In recent years the rapid development of “big data analytics” has created a surge within pharmaceutical companies to harness and leverage data from the entire value chain to drive actionable insights. Although other departments within pharmaceutical companies have long been focused on utilizing data driven insights, modern pharmacovigilance departments are just recently starting to fully incorporate a data-and-analytics-first approach to GVP IX signal detection, GVP IX signal validation, and GVP IX signal prioritization.
At Advera Health Analytics, our sole focus is on operationalizing pharmacovigilance analytics through the Evidex® platform. Based on conversations with our current and prospective customers, we’ve identified three overarching trends that are driving both process adoption, and technology acquisition.
Fill out the form above to download this White Paper.